Traduction de «medicinal products unit also published » (Néerlandais → Français) :

In December 2008 the Homeopathic and Herbal Medicinal Products Unit also published circular 533 regarding the notification of traditional herbal medicines. Finally, a specific database was developed for this.
In December 2008 the Homeopathic and Herbal Medicinal Products Unit also published circular 533 regarding the notification of traditional herbal medicines. Finally, a specific database was developed for this.

Some current and future projects of the Veterinary Medicines unit In addition to active participation in numerous projects with an impact on different departments or services or even on the entire organisation, there are also a number of projects specifically for the Veterinary Medicines unit, such as: ●● The computerisation of the databases for
Some current and future projects of the Veterinary Medicines unit In addition to active participation in numerous projects with an impact on different departments or services or even on the entire organisation, there are also a number of projects specifically for the Veterinary Medicines unit, such as: ●● The computerisation of the databases for

The inspection units also support the Judicial Authority and are, in addition to their control and inspection tasks, responsible for dealing with and investigating any complaints relating to the legal requirements on medicines and/or health products.
The inspection units also support the Judicial Authority and are, in addition to their control and inspection tasks, responsible for dealing with and investigating any complaints relating to the legal requirements on medicines and/or health products.

Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).
Unit I Unit I is responsible for the tasks of the secretariat of the commission for the establishment of retail pharmacies, of the secretariat of the commission for the recognition of pharmacists-clinical biologists, of the retail pharmacies registry and plays an important role in the problems of products in the “grey area” (these are “borderline” products whose exact status has to be determined: is it a medicine or not?).

Also supporting the broad expansion have been landmark data first presented in 2008, and published in early 2009 in “The New England Journal of Medicine,” that showed the significant anti-cancer benefit of Zometa in reducing the risk of cancer recurrence or death in premenopausal women with hormone-sensitive, earlystage breast cancer.
Cette large progression a été soutenue par de nouveaux résultats d’une étude pivot présentés initialement en 2008 et publiés début 2009 dans «The New England Journal of Medicine» faisant état des bénéfices anticancer importants du Zometa dans le risque de récidive ou de décès chez les femmes préménopausées atteintes d’un cancer du sein hormono-dépendant précoce.

Working through the backlog 54 –– Medicinal products for human use 54 –– Veterinary medicines Unit 55
Working through the backlog 54 –– Medicinal products for human use 54 –– Veterinary medicines Unit 55

Unit I also deals with inspections of retail and hospital pharmacies, stocks of medicines in care institutions and at the veterinarians, and is charged with the supervision of the distribution of medical devices.
Unit I also deals with inspections of retail and hospital pharmacies, stocks of medicines in care institutions and at the veterinarians, and is charged with the supervision of the distribution of medical devices.

In anticipation of changes to the product portfolio in the US, which includes expected approvals for a number of new specialty medicines but also the loss of market exclusivity for Diovan and other medicines in the next few years, Novartis has further streamlined its US business in Pharmaceuticals to maximize the potential of the changing portfolio in both primary care and specialty markets.
Novartis anticipe les changements qui vont intervenir au cours des années à venir dans son portefeuille de produits aux Etats-Unis, notamment les autorisations attendues pour de nouvelles spécialités mais aussi la perte de l’exclusivité du marché pour Diovan et d’autres médicaments. C’est ainsi que Pharmaceuticals a encore rationalisé ses opérations américaines pour maximiser le potentiel d’un portefeuille en plein changement, à la fois dans les soins de santé primaires et dans les marchés des spécialités.

Thanks to the introduction of a proactive vigilance policy within the FAMHP via the PROACTIVE VIGILANCE spearhead, the safety profile of medicines and health products will be better known, thereby also promoting safer use of these products.
Thanks to the introduction of a proactive vigilance policy within the FAMHP via the PROACTIVE VIGILANCE spearhead, the safety profile of medicines and health products will be better known, thereby also promoting safer use of these products.

At a time of converging trends, which include rising global demand for medicines but also increasing cost-containment pressures, the new leadership team appointed in January 2010 has established priorities to deliver innovation, growth and productivity consistent with the Group’s aspiration to be the world’s most successful and respected healthcare company.
Au moment où se produit une convergence des tendances, notamment une hausse de la demande de médicaments dans le monde entier mais aussi une pression croissante pour contenir les coûts, la nouvelle équipe dirigeante mise en place en janvier 2010 a défini ses priorités afin de promouvoir l’innovation, la croissance et la productivité qui permettront de répondre à l’aspiration du Groupe à être l'entreprise des soins de santé la plus performante et la plus respectée au monde.